On-Demand Webinar: Bacteriophage Therapy: The Enemy of My Enemy is My Friend

On-Demand Webinar: Bacteriophage Therapy: The Enemy of My Enemy is My Friend

Presenter: Robert T. Schooley, MD

Release date: August 17, 2021
Expiration date: August 17, 2022
CME Credit Available: 1.25 AMA PRA Category 1 Credits

Overview

Assessment of Needs

Widespread antibiotic use in clinical medicine and the livestock industry has contributed to the global spread of multidrug-resistant bacterial pathogens. Bacterial viruses, or bacteriophages, are promising therapeutic agents against multi-drug resistant microbes. This webinar will discuss the management of multi-drug resistant infections and the recent advancements in treatment with the use of bacteriophage therapy. Dr Robert T. Schooley is one of the leaders in this new investigational therapeutic approach, which transforms viruses into targeted therapies for devastating bacterial infections.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe the important advancements in bacteriophage therapeutics
  • Describe the potential applications of bacteriophage therapeutics in clinical practice

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Presenter Disclosure

Dr Schooley has served as a consultant to CytoDyn and has receives royalties from Antiva Biosciences and CytoDyn. He serves on advisory boards for and has received advisory fees paid to his institution from Gilead Sciences, Inc. and VIR Biotechnology. His spouse, Dr Benson, serves on a data and safety monitoring board for GlaxoSmithKline and ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 08/17/21)

All relevant financial relationships have been mitigated.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co., Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.

Course Materials

How to Claim Credit

  1. Start the Activity by clicking "START COURSE" located above.
    Please note that the "START COURSE" will no longer be visible once you clicked it once.
  2. Watch the webinar here.
  3. Return to this page and follow this link to the evaluation form.
  4. Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
  5. Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.